GSK plc 6-K, filed Sep 26, 2022
GSK plc (GSK)
6-K
2022-09-26
For: 2022-09-26
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on September 26, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 26 September 2022, London UK
Iain Mackay, Chief Financial Officer, to retire from GSK, Julie
Brown appointed as successor
GSK plc (LSE/NYSE: GSK) today announced that Iain Mackay, Chief
Financial Officer (CFO), has decided to retire from GSK. The Board
has agreed that he will step down as CFO and as an Executive
Director of the Board in May 2023.
The Board has selected Ms Julie Brown, currently Chief Operating
and Financial Officer, Burberry Group plc, as successor to Iain.
Julie is a highly respected CFO with extensive experience in the
biopharma and medtech sectors, having previously worked at
AstraZeneca plc and Smith & Nephew plc; and as a non-executive
director and Audit Chair of Roche Holding AG.
Julie will join GSK in April 2023 and will work with Iain to
transition responsibilities, taking responsibility as CFO and as an
Executive Director of GSK on 1 May 2023.
Emma Walmsley, Chief Executive Officer, GSK,
said: "I
want to thank Iain for all he's done for GSK, and for his
leadership and support to our people. He has played a very
significant role to help deliver the reshaping of GSK and to
improve our operating and financial performance. I am absolutely
delighted that Julie will be joining the leadership team as his
successor. Julie is a highly experienced CFO with a tremendous
understanding of the biopharma sector. We also share a strong
passion for people development, diversity, inclusion and
sustainability. I am looking forward to working together to deliver
progress for patients, shareholders and our
people."
Jonathan Symonds, Chair, GSK, said: "On
behalf of the Board I would like to thank Iain for his significant
contribution at GSK. He has been a highly valued member of the
Board and has provided strong support to Emma and the management
team. We are delighted that Julie will join the Board as Iain's
successor. She is a CFO of exceptional calibre and experience and I
look forward to the contribution she will
make."
Notes to Editors
Biography
Julie serves as Chief Operating and Financial Officer, Burberry
Group plc and an Executive Director. She joined Burberry from Smith
& Nephew where she was the Group CFO from 2013-2017. Before
this, she was Interim Group CFO of AstraZeneca, having worked at
the company for 25 years in finance, commercial and strategic
roles.
Julie has also served as a Non-Executive Director and Audit Chair
of Roche Holding AG. She is also co-Chair of the Prince's
Accounting for Sustainability Project's CFO Leadership Network, a
member of the Prime Minister's Business Council, the Business
Advisory Board to the Mayor of London and Patron of Oxford
University Women in Business. Julie is a Fellow of the Institute of
Chartered Accountancy and the Institute of Tax and qualified with
KPMG International Limited.
Shareholding information and regulatory disclosure
Ms Brown holds 519 shares in GSK. The Company confirms that, in
respect of Listing Rule 9.6.13R(1), Ms Brown is currently an
Executive Director of Burberry Group plc and, prior to her
appointment to GSK, a Non-Executive Director of Roche Holding AG.
The Burberry directorship will cease before she commences her
employment with GSK and Ms Brown has resigned from the Roche Board.
There are no details to disclose in respect of Listing Rule
9.6.13R(2-6).
Appointment and selection process
Ms Brown's appointment was made by the Board on the recommendation
of the Nominations & Corporate Governance Committee following
an extensive search and selection process using external search
firms, each of which was a signatory of the Voluntary Code of
Conduct for Executive Search Firms. A diverse list of candidates
was compiled who were evaluated against an agreed set of criteria,
to identify the most suitable candidate.
Remuneration
The Remuneration Committee considered the remuneration arrangements
that would be appropriate to enable the Company to recruit and
retain an experienced CFO to meet the criteria for the role within
the Company's current shareholder-approved remuneration policy.
Given Ms Brown's wealth of experience in the role and of the
industry it was agreed that her remuneration should be set in line
with the current CFO's remuneration, as follows.
Ms Brown's remuneration arrangements
|
|
£
|
Notes
|
|
Base salary
|
£915,335
|
The comparator group for pay for the CFO remains the European
cross-industry comparator group set out in our Annual
Report.
|
|
Annual bonus
|
£915,335
|
The on-target bonus would be 100%, with a maximum of 300% for
incremental exceptional performance as for the existing
CFO.
|
|
Award of Long Term Incentives (LTIs)
|
£1,830,670
|
This assumes an expected value of 50% of an award of performance
shares under the Company's 2017 Performance Share Plan at a 4x
multiple of base salary as for the existing CFO.
|
|
Share Ownership Requirement (SOR)
|
3x
|
This is in line with GSK's shareholder approved executive
remuneration policy approved earlier in 2022.
|
|
Pension
|
|
Pension arrangements will be in line with those of the wider UK
workforce in line with GSK's commitment from 1 January
2023.
|
|
Benefits
|
|
Benefits will be in line with GSK's policy and arrangements for
other executives based in the UK to support them in undertaking
their role.
|
Ms Brown's contract of employment will be available for inspection
at the Company's registered office and on GSK's website, gsk.com,
in due course.
The following Buyout Payments will be provided:
●
a
sum ("the Bonus Buyout") equivalent to Ms Brown's on-target
Burberry bonus for the period from 1 April, 2022 to 31 March, 2023,
which she will forego on leaving Burberry,
●
a
sum ("the LTI Buyout") equivalent to the aggregate value of (i) her
outstanding Burberry LTIs and SIP shares which will be lost on
leaving Burberry, at a price equivalent to the average price of
such shares for the one-month period ending on 7 September, 2022,
and (ii) the value of any dividend equivalents accruing on those
shares between their date of award and her departure from Burberry.
Given that the Burberry LTIs are not subject to a performance
measure, and only to a performance underpin, no discount will be
applied to the value of the shares so
calculated.
The timing of these payments will be as follows. A cash amount
equivalent to:
●
the
Bonus Buyout and one-third of 85% of the LTI Buyout will be paid to
her in the first payroll following the commencement of her
employment with GSK;
●
one-third
of 85% of the LTI Buyout will be paid to her in the first payroll
following the first anniversary of the commencement of her
employment; and,
●
one-third
of 85% of the LTI Buyout will be paid to her in the first payroll
following the second anniversary of the commencement of her
employment.
In addition, she will be paid an amount equivalent to 15% of the
LTI Buyout in the first payroll following the commencement of her
employment. Ms Brown has agreed that she will invest the net of tax
proceeds of this 15% tranche in GSK plc Ordinary Shares at the
first reasonably available opportunity having sought dealing
clearance and that she will then continue to hold those shares for
a period of at least two years. Ms Brown will be required to build
and maintain over time a holding of shares in GSK equivalent to a
value of three times' base salary.
Mr Mackay's remuneration
To support the succession and transition process, Mr Mackay will
continue to receive his base salary until he leaves GSK. He will be
eligible to receive bonuses which will be determined by the
Remuneration Committee based on a combination of business and
individual performance for his service during 2022 and 2023. He
will not be eligible to receive any further LTI awards. However, he
will retain all his existing long-term incentive awards. His
executive service contract will end on 31 December 2023. He will be
required to maintain his share ownership requirement in accordance
with the Company's shareholder approved remuneration policy for a
two year period.
Full details will be provided in the Remuneration
Report.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
September 26, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|